Search company, investor...

Raze Therapeutics


Dead | Dead

Total Raised


About Raze Therapeutics

Raze Therapeutics is dedicated to the discovery and development of a new class of oncology therapeutics that target fundamental metabolic pathways essential to cancer growth and survival. By selectively targeting one-carbon (1C) metabolism using its proprietary platform, Raze is developing a pipeline of 1C metabolism therapeutics across a range of solid and hematologic cancers, including genetically-defined cancers. Raze is led by an experienced management team with a proven track record for building successful biotech companies and recognized scientific leaders in metabolism and cancer biology.

Headquarters Location

400 Technology Square 10th Floor

Cambridge, Massachusetts, 02139,

United States


Missing: Raze Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Raze Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Raze Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Raze Therapeutics in 1 CB Insights research brief, most recently on Oct 17, 2022.

Expert Collections containing Raze Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Raze Therapeutics is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Raze Therapeutics Patents

Raze Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • EC 1.1.1
  • Experimental cancer drugs
  • Protein kinase inhibitors
patents chart

Application Date

Grant Date


Related Topics




Experimental cancer drugs, Transcription factors, Protein kinase inhibitors, EC 2.1.1, Proteins


Application Date


Grant Date



Related Topics

Experimental cancer drugs, Transcription factors, Protein kinase inhibitors, EC 2.1.1, Proteins



Latest Raze Therapeutics News

Raze Therapeutics

Oct 1, 2015

Verify here. The information provided by is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: All rights reserved. All other trademarks recognized. Copyright © 1997-2015 BioPortfolio Limited. Site developed by Alacrify Ltd .

Raze Therapeutics Frequently Asked Questions (FAQ)

  • Where is Raze Therapeutics's headquarters?

    Raze Therapeutics's headquarters is located at 400 Technology Square, Cambridge.

  • What is Raze Therapeutics's latest funding round?

    Raze Therapeutics's latest funding round is Dead.

  • How much did Raze Therapeutics raise?

    Raze Therapeutics raised a total of $24M.

  • Who are the investors of Raze Therapeutics?

    Investors of Raze Therapeutics include M Ventures, Astellas Venture Management, MPM Capital, Atlas Venture, Novartis Venture Funds and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.